Cargando…

Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status

Transcatheter aortic valve implantation (TAVI) is the standard of care for symptomatic severe aortic stenosis. Antithrombotic therapy is required after TAVI to prevent thrombotic complications but it increases the risk of bleeding events. Current clinical guidelines are mostly driven by expert opini...

Descripción completa

Detalles Bibliográficos
Autores principales: Greco, Antonio, Capodanno, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203879/
https://www.ncbi.nlm.nih.gov/pubmed/32382318
http://dx.doi.org/10.15420/icr.2019.24
_version_ 1783529954323988480
author Greco, Antonio
Capodanno, Davide
author_facet Greco, Antonio
Capodanno, Davide
author_sort Greco, Antonio
collection PubMed
description Transcatheter aortic valve implantation (TAVI) is the standard of care for symptomatic severe aortic stenosis. Antithrombotic therapy is required after TAVI to prevent thrombotic complications but it increases the risk of bleeding events. Current clinical guidelines are mostly driven by expert opinion and therefore yield low-grade recommendations. The optimal antithrombotic regimen following TAVI has yet to be determined and several randomised controlled trials assessing this issue are ongoing. The purpose of this article is to critically explore the impact of antithrombotic drugs, especially anticoagulants, on long-term clinical outcomes following successful TAVI.
format Online
Article
Text
id pubmed-7203879
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-72038792020-05-07 Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status Greco, Antonio Capodanno, Davide Interv Cardiol Structural Transcatheter aortic valve implantation (TAVI) is the standard of care for symptomatic severe aortic stenosis. Antithrombotic therapy is required after TAVI to prevent thrombotic complications but it increases the risk of bleeding events. Current clinical guidelines are mostly driven by expert opinion and therefore yield low-grade recommendations. The optimal antithrombotic regimen following TAVI has yet to be determined and several randomised controlled trials assessing this issue are ongoing. The purpose of this article is to critically explore the impact of antithrombotic drugs, especially anticoagulants, on long-term clinical outcomes following successful TAVI. Radcliffe Cardiology 2020-04-23 /pmc/articles/PMC7203879/ /pubmed/32382318 http://dx.doi.org/10.15420/icr.2019.24 Text en Copyright © 2020, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Structural
Greco, Antonio
Capodanno, Davide
Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
title Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
title_full Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
title_fullStr Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
title_full_unstemmed Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
title_short Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
title_sort anticoagulation after transcatheter aortic valve implantation: current status
topic Structural
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203879/
https://www.ncbi.nlm.nih.gov/pubmed/32382318
http://dx.doi.org/10.15420/icr.2019.24
work_keys_str_mv AT grecoantonio anticoagulationaftertranscatheteraorticvalveimplantationcurrentstatus
AT capodannodavide anticoagulationaftertranscatheteraorticvalveimplantationcurrentstatus